Decrease synaptic activity
| Agent | Sponsor | Type of Therapy | Phase of Development | Clinical Trial Identifier | Status/Findings |
|---|---|---|---|---|---|
| Memantine | Wayne State University | NMDA receptor antagonist | Phase 3 | NCT03858270 | Recruiting |
| Perampanel | AMPA receptor antagonist | Preclinical | Protects against phospho-α-Syn aggregates in α-Syn PFF mice (Ueda et al., 2021) |
AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid.